Evidence map›Paper›PMID 35811712›Full record

ArticleFrontiers in cardiovascular medicine2022

Coronary Flow Evaluation in Heart Transplant Patients Compared to Healthy Controls Documents the Superiority of Coronary Flow Velocity Reserve Companion as Diagnostic and Prognostic Tool.

Annagrazia Cecere, Peter L M Kerkhof, Giovanni Civieri, Annalisa Angelini, Antonio Gambino, Angela Fraiese, Tomaso Bottio, Elena Osto, Giulia Famoso, Marny Fedrigo and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Annagrazia CecereDepartment of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy.
Peter L M KerkhofDepartment of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Amsterdam, Netherlands.
Giovanni CivieriDepartment of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy.
Annalisa AngeliniCardiovascular Pathology Unit, Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy.
Antonio GambinoDivision of Cardiac Surgery, University of Padua, Padua, Italy.
Angela FraieseDivision of Cardiac Surgery, University of Padua, Padua, Italy.
Tomaso BottioDivision of Cardiac Surgery, University of Padua, Padua, Italy.
Elena OstoCardiology, University Heart Center, University Hospital of Zürich, Zurich, Switzerland.
Giulia FamosoDepartment of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy.
Marny FedrigoCardiovascular Pathology Unit, Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy.
Enrico GiacominDepartment of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy.
Giuseppe ToscanoDivision of Cardiac Surgery, University of Padua, Padua, Italy.
Roberta MontisciClinical Cardiology, AOU Cagliari, Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy.
Sabino IlicetoDepartment of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy.
Gino GerosaDivision of Cardiac Surgery, University of Padua, Padua, Italy.
Francesco TonaDepartment of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Distinct contributions by functional or structural alterations of coronary microcirculation in heart transplantation (HT) and their prognostic role have not been fully elucidated. We aimed to identify the mechanisms of coronary microvascular dysfunction (CMD) in HT and their prognostic implications. Methods: 134 patients, surviving at least 5 years after HT, without evidence of angiographic vasculopathy or symptoms/signs of rejection were included. 50 healthy volunteers served as controls. All underwent the assessment of rest and hyperemic coronary diastolic peak flow velocity (DPV Results: Based on CFVR and DPV Conclusion: A normal CFVR could hide detection of microvasculopathy with high flow resistance and low flow velocities at rest. This microvasculopathy seems to be secondary to factors unrelated to HT (less rejections and more often diabetes). The combined use of CFVR and CCFVR provides more complete clinical and prognostic information on coronary microvasculopathy in HT.

Indexed as

companion metriccoronary flow reserveheart transplantmicrocirculationprognosis

Identifiers

PMID35811712
PMCPMC9263115

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.